Aytu Bioscience Stock Today
| AYTU Stock | USD 2.38 0.06 2.59% |
PerformanceGood
| Odds Of DistressAbout Average
|
Aytu BioScience is selling for under 2.38 as of the 18th of July 2025; that is 2.59 percent increase since the beginning of the trading day. The stock's last reported lowest price was 2.31. Aytu BioScience has 50 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. The performance scores are derived for the period starting the 19th of April 2025 and ending today, the 18th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of February 2017 | Category Healthcare | Classification Health Care |
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado. The company has 8.98 M outstanding shares of which 492.41 K shares are presently shorted by private and institutional investors with about 0.17 trading days to cover. More on Aytu BioScience
Moving together with Aytu Stock
Moving against Aytu Stock
Follow Valuation Profit Patterns Daily Balance Of Power
Check how we calculate scores
Aytu Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO, Director | Joshua Disbrow | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsAytu BioScience can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aytu BioScience's financial leverage. It provides some insight into what part of Aytu BioScience's total assets is financed by creditors.
| |||||
Aytu BioScience (AYTU) is traded on NASDAQ Exchange in USA. It is located in Denver Corporate Center III, Denver, CO, United States, 80237 and employs 102 people. Aytu BioScience is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.37 M. Aytu BioScience conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 8.98 M outstanding shares of which 492.41 K shares are presently shorted by private and institutional investors with about 0.17 trading days to cover.
Aytu BioScience currently holds about 23.81 M in cash with (1.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38.
Check Aytu BioScience Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Aytu BioScience is $21.37 Million. Aytu BioScience shows 7.57 percent of its outstanding shares held by insiders and 27.32 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Aytu Ownership Details
Aytu Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Tower Research Capital Llc | 2025-03-31 | 4.7 K | |
| Mccormack Advisors International | 2025-03-31 | 3.6 K | |
| Advisor Group Holdings, Inc. | 2025-03-31 | 300 | |
| Morgan Stanley - Brokerage Accounts | 2025-03-31 | 290 | |
| Ubs Group Ag | 2025-03-31 | 262 | |
| Wells Fargo & Co | 2025-03-31 | 124 | |
| Bank Of America Corp | 2025-03-31 | 103 | |
| Atlantic Trust Group, Llc | 2025-03-31 | 83.0 | |
| Sbi Securities Co Ltd | 2025-03-31 | 61.0 | |
| Nantahala Capital Management, Llc | 2025-03-31 | 1.1 M | |
| Stonepine Capital Management Llc | 2025-03-31 | 463.7 K |
Aytu BioScience Historical Income Statement
Aytu Stock Against Markets
Aytu BioScience Corporate Management
| Russ McMahen | Senior Development | Profile | |
| Christopher Brooke | Chief Officer | Profile | |
| Margaret Cabano | Vice Operations | Profile | |
| Topher Brooke | Chief Officer | Profile | |
| Greg Pyszczymuka | Chief Officer | Profile |
Already Invested in Aytu BioScience?
The danger of trading Aytu BioScience is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aytu BioScience is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aytu BioScience. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aytu BioScience is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.